Pesquisar
Lipocine Inc
LPCNAdicionar à lista de desejos
2.220USD
0.0000.00%
Horário de mercado 09/18, 13:23（ET）
18.30MValor de mercado
PerdaP/L TTM
Mais detalhes de Lipocine Inc Empresa
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Lipocine Inc Perfil
Código da empresaLPCN
Nome da EmpresaLipocine Inc
Data de listagemMar 21, 2014
CEOPatel (Mahesh V)
Número de funcionários16
Tipo de títulosOrdinary Share
Fim do ano fiscalMar 21
Endereço675 S Arapeen Dr Ste 202
CidadeSALT LAKE CITY
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal84108-1295
Telefone18019947383
Sitehttps://www.lipocine.com/
Código da empresaLPCN
Data de listagemMar 21, 2014
CEOPatel (Mahesh V)
Executivos da empresa Lipocine Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
203.80K
+79.98%
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
203.80K
+79.98%
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
203.80K
+79.98%
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
160.68K
+31.12%
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
160.68K
+31.12%
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
160.68K
+31.12%
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.86K
+9.40%
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.86K
+9.40%
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.86K
+9.40%
Ms. Krista Fogarty
Ms. Krista Fogarty
Principal Accounting Officer, Corporate Controller
Principal Accounting Officer, Corporate Controller
1.40K
+23.64%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
203.80K
+79.98%
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
203.80K
+79.98%
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
203.80K
+79.98%
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
160.68K
+31.12%
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
160.68K
+31.12%
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
160.68K
+31.12%
Perguntas frequentes
Quem são os cinco principais acionistas de Lipocine Inc?
Os cinco principais acionistas de Lipocine Inc são: Mr. John W. Higuchi
Quantas instituições possuem ações da Lipocine Inc (LPCN)?
Em 2026Q1, 45 instituições possuíam ações da Lipocine Inc, com valor de mercado aproximado de 2.08M, representando 25.27% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em 1533872.00.